H. Lundbeck ASFRA:LDBA +3.13%81 ROA % is 12.71% as of Mar. 2026, which is 113% above its 10-year median of 5.98. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, H. Lundbeck AS ranks better than 72.04% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. H. Lundbeck AS's annualizedNet Income for the quarter that ended in Mar. 2026 was €887 Mil.
H. Lundbeck AS's average Total Assets over the quarter that ended in Mar. 2026 was €6,984 Mil. Therefore, H. Lundbeck AS's annualized ROA % for the quarter that ended in Mar. 2026 was 12.71%.
The historical rank and industry rank for H. Lundbeck AS's ROA % or its related term are showing as below:
FRA:LDBA'
s ROA % Range Over the Past 10 Years
Min: 3.73 Med: 5.98 Max: 18.27
Current: 7.02
During the past 13 years, H. Lundbeck AS's highest ROA % was 18.27%. The lowest was 3.73%. And the median was 5.98%.
FRA:LDBA's ROA % is ranked better than 72.04% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs FRA:LDBA: 7.02
H. Lundbeck AS (FRA:LDBA) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
H. Lundbeck AS ROA % Related Terms
H. Lundbeck AS ROA % Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's ROA % distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
H. Lundbeck AS (FRA:LDBA) has a ROA % of 12.71% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on H. Lundbeck AS and its competitors. This is 113% above median its historical median of 5.98. Over the past decade, H. Lundbeck AS's ROA % has ranged from 3.73 to 18.27. According to the industry distribution chart, H. Lundbeck AS ranks #281 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is H. Lundbeck AS's ROA % too high?
H. Lundbeck AS's current ROA % of 12.71% is 113% above median its 10-year median of 5.98. Over the past 10 years, this metric has ranged from a low of 3.73 to a high of 18.27. The Drug Manufacturers industry median ROA % is 2.72. H. Lundbeck AS's value of 12.71% is 367.3% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #281 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #281 out of 1005 companies for ROA %. This puts H. Lundbeck AS in the upper half of its industry. The industry median ROA % is 2.72. H. Lundbeck AS's value of 12.71% is 367.3% above this benchmark. Historically, H. Lundbeck AS's own ROA % has ranged from 3.73 to 18.27 over the past decade. While the company's 10-year median is 5.98 vs. the industry median of 2.72, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current ROA % of 12.71% is 367.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current ROA % is 12.71%, which is 113% above median its own 10-year median of 5.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current ROA % is 12.71%, which is 113% above median its 10-year median of 5.98 and 367.3% above the Drug Manufacturers industry median of 2.72. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current ROA % is 12.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for FRA:LDBA:
ROA %: 12.71% (113% above median its 10-year median of 5.98)
GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
Industry Position: 367.3% above the Drug Manufacturers median (#281 of 1005)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score
Get the complete analysis for FRA:LDBA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
